Cyclerion Therapeutics Business Summary

Cyclerion Therapeutics, Inc. (CYCN) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, milestone-based partnerships, and the monetization of its legacy soluble guanylate cyclase (sGC) stimulator portfolio. Following a transformational relaunch in late 2025, the company operates through a singular human therapeutics segment focused on neuropsychiatry. Its core business model centers on the development of CYC-126, a precision-delivered, anesthetic-based therapy for treatment-resistant depression (TRD) that utilizes a closed-loop platform integrating real-time EEG monitoring and algorithm-guided dosing. Cyclerion competes directly with CNS-focused firms such as Cerevel Therapeutics, Spark Therapeutics, Reneo Pharmaceuticals, and Crinetics Pharmaceuticals, positioning itself as a niche pioneer in individualized, tech-enabled neuropsychiatric interventions rather than traditional broad-spectrum pharmacology. Originally spun off from Ironwood Pharmaceuticals in 2019, the company was founded by Peter Hecht, Ph.D., and Brian Cali. The current leadership team is headed by President and CEO Regina Graul, Ph.D., who previously held senior roles at EQRx and led Cyclerion’s olinciguat franchise, and CFO Rhonda M. Chicko, a former finance executive at Editas Medicine and Ironwood. The company is supported by a high-profile Clinical Advisory Board formed in February 2026, featuring industry luminaries such as Dr. Husseini Manji and Dr. Lawrence Olanoff. Cyclerion’s board is chaired by Errol De Souza, Ph.D., and includes notable directors such as Steven Hyman and Dina Katabi, with institutional backing from major shareholders including Vanguard Group, BlackRock, and Two Sigma Investments.